Though only formed in 2015, LivaNova’s history in the medical space stretches back to the founding of Sorin Biomedica in 1956, which merged with Cyberonics to form LivaNova. Combining their specialties in cardiovascular disease and neuromodulation, LivaNova has remained at the forefront of innovation in therapeutic areas affecting the head and heart.
The company creates advanced medical devices and treatments in areas like cardiopulmonary care and neuromodulation, helping both patients and healthcare professionals worldwide. With its diverse range of products and a presence in over 100 countries, LivaNova is well-positioned as a leader in the field, continuously striving to improve the lives of those who need it most.
Recently, LivaNova has made waves with its new treatment for obstructive sleep apnea (OSA), a condition where breathing stops and starts during sleep. Its device, the aura6000, has shown promising results in a major clinical trial. This breakthrough could change the way OSA is treated, and the trial results were strong enough for LivaNova to consider moving forward with approval from the FDA. If successful, the aura6000 could become a major competitor in the sleep apnea market, positioning LivaNova for exciting growth in a new and expanding field.
Kirsty
Company Specialist at Welcome to the Jungle
